Drug intelligence / Profile preview

KW-021

Development stage: Preclinical
Lead developer: Kawin Technology
Modality: Interferons → Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Injection

Overview

KW-021 is a pegylated recombinant interferon-alpha being developed by Kawin Technology for the treatment of chronic Hepatitis B. By conjugating the interferon protein with polyethylene glycol (PEG), the drug achieves a prolonged half-life and sustained therapeutic plasma concentrations compared to non-pegylated interferons. KW-021 exerts its antiviral effects by binding to the Type I interferon receptor (IFNAR), which triggers the JAK-STAT signaling pathway. This leads to the induction of various interferon-stimulated genes (ISGs) that inhibit viral replication, degrade viral RNA, and enhance the host's immune response by activating natural killer cells and T-lymphocytes to target Hepatitis B virus (HBV)-infected hepatocytes.

Other names: Peginterferon alfa (new)-3Peginterferon alfa-new-3

Targets

IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on KW-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KW-021.

Explore the full profile